Inhibitory effect of Zn2+ in zinc-containing beta-tricalcium phosphate on resorbing activity of mature osteoclasts.
Long term effect of the growing instability of the bone-implant interface due to bone resorption at the interface is a problem for the implants, including bioactive ceramics. Zn2+ -containing tricalcium phosphate (ZnTCP) is a material which may overcome this problem. The present study aims to clarify whether Zn2+ -containing tricalcium phosphate (ZnTCP) ceramics with a Zn2+ content of 0.316 (ZnTCP316) and 0.633 (ZnTCP633) wt % suppress resorption by mature osteoclasts in vitro. Suppression would be due to an increase in the number of apoptotic osteoclasts and the inhibition of the resorbing activity of osteoclasts, the latter being the major mechanism of the suppression. The number of apoptotic osteoclasts was significantly 6.3 times higher with ZnTCP633 than with tricalcium phosphate ceramic (TCP) after 24-h culture. The net contribution to resorption of this change in apoptotic cell numbers is much smaller than that of the change in resorbing activity. The osteoclasts cultured on ZnTCP formed fewer actin rings than those cultured on the TCP. The mRNA expression of CAII and cathepsin K/OC2 in the osteoclasts on ZnTCP633 was downregulated 0.5-fold and 0.6-fold, respectively, compared with that on the TCP. The volume of resorption pits was downregulated 0.4-fold in the ZnTCP633 than that in TCP. These results suggest that ZnTCPs suppressed the resorbing activity of mature osteoclasts probably through a local increase in the level of Zn2+. Bone substitutes or coating layers containing ZnTCP would be promising biomaterials from the viewpoint of counteracting osteoclastic bone resorption at the bone-implant interface.
Yamada
Yasutaka
Y
Graduate School of Comprehensive Human Science, University of Tsukuba, 2-1-1 Tennodai, Tsukuba, Ibaraki 305-8572, Japan. yasutaka-yamada@aist.go.jp
Ito
Astuo
A
Kojima
Hiroko
H
Sakane
Masataka
M
Miyakawa
Shumpei
S
Uemura
Toshimasa
T
LeGeros
Racquel Z
RZ
D000199:Actins / Q000096:biosynthesis / Q000235:genetics; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001862:Bone Resorption / Q000473:pathology* / Q000517:prevention & control*; D002118:Calcium / Q000378:metabolism; D002130:Calcium Phosphates / Q000737:chemistry / Q000494:pharmacology*; D002448:Cell Adhesion / Q000187:drug effects; D002469:Cell Separation; D003470:Culture Media; D010010:Osteoclasts / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology*; D010758:Phosphorus / Q000032:analysis; D012313:RNA / Q000096:biosynthesis / Q000235:genetics; D011817:Rabbits; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015032:Zinc / Q000737:chemistry / Q000494:pharmacology*
D000199:Actins; D002130:Calcium Phosphates; D003470:Culture Media; D010758:Phosphorus; D012313:RNA; D015032:Zinc; C018392:tricalcium phosphate; D002118:Calcium